A novel cryogenic heat pipe, oscillating heat pipe (OHP), which consists of an 4 × 18.5 cm evaporator, a 6 × 18.5 cm condenser, and 10 cm length of adiabatic section, has been developed and experimental characterization conducted. Experimental results show that the maximum heat transport capability of the OHP reached 380W with average temperature difference of 49 °C between the evaporator and condenser when the cryogenic OHP was charged with liquid nitrogen at 48% (v/v) and operated in a horizontal direction. The thermal resistance decreased from 0.256 to 0.112 while the heat load increased from 22.5 to 321.8 W. When the OHP was operated at a steady state and an incremental heat load was added to it, the OHP operation changed from a steady state to an unsteady state until a new steady state was reached. This process can be divided into three regions: (I) unsteady state; (II) transient state; and (III) new steady state. In the steady state, the amplitude of temperature change in the evaporator is smaller than that of the condenser while the temperature response keeps the same frequency both in the evaporator and the condenser. The experimental results also showed that the amplitude of temperature difference between the evaporator and the condenser decreased when the heat load increased.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2888510 | PMC |
http://dx.doi.org/10.1016/j.ijheatmasstransfer.2009.03.013 | DOI Listing |
JACS Au
January 2025
Instituto de Química, Universidade Federal do Rio Grande do Sul-UFRGS, Av. Bento Gonçalves 9500, 91501-970 Porto Alegre, Rio Grande do Sul, Brazil.
Understanding the mechanism of drug action in biological systems is facilitated by the interactions between small molecules and target chiral biomolecules. In this context, focusing on the enantiomeric recognition of carbohydrates in solution through steady-state fluorescence emission spectroscopy is noteworthy. To this end, we have developed a third generation of chiral optical sensors for carbohydrates, distinct from all of those previously presented, which interact with carbohydrates to form non-covalent probe-analyte interactions.
View Article and Find Full Text PDFFront Pharmacol
January 2025
Certara Inc., Melbourne, VIC, Australia.
Exposure-response (ER) analyses are routinely performed as part of model-informed drug development to evaluate the risk-to-benefit ratio for dose selection, justification, and confirmation. For logistic regression analyses with binary endpoints, several exposure metrics are investigated, based on pharmacological plausibility, including time-averaged concentration to event (C). C is informative because it accounts for dose interruptions, modifications, and reductions and is therefore often compared against ER relationships identified using steady-state exposures.
View Article and Find Full Text PDFSci Rep
January 2025
Department of Mathematics, College of Science Al-Zulfi, Majmaah University, Al-Majmaah 11952, Saudi Arabia.
This study aims at investigating the dynamics of sexually transmitted infectious disease (STID), which is serious health concern. In so doing, the integer order STID model is progressed in to the time-delayed non-integer order STID model by introducing the Caputo fractional derivatives in place of integer order derivatives and including the delay factors in the susceptible and infectious compartments. Moreover, unique existence of the solution for the underlying model is ensured by establishing some benchmark results.
View Article and Find Full Text PDFThe human () gene encodes a plasma membrane protein SLC39A8 (ZIP8) that mediates the specific uptake of the metals Cd, Mn, Zn, Fe, Co, and Se Pathogenic variants within are associated with congenital disorder of glycosylation type 2 (CDG type II) or Leigh-like syndrome. However, numerous mutations of uncertain significance are also linked to different conditions or benign traits. Our study characterized 21 variants and measured their impact on protein localization and intracellular levels of Cd, Zn, and Mn We identified four variants that disrupt protein expression, five variants with high retention in the endoplasmic reticulum, and 12 variants with localization to the plasma membrane.
View Article and Find Full Text PDFDrug Metab Dispos
January 2025
Global Clinical Development, Chiesi Farmaceutici SpA, Parma, Italy.
Tanimilast is an inhaled phosphodiesterase-4 inhibitor currently in phase III clinical development for treating chronic obstructive pulmonary disease and asthma. This trial aimed to characterize the pharmacokinetics, mass balance, and metabolite profiling of tanimilast. Eight healthy male volunteers received a single dose of nonradiolabeled tanimilast via powder inhaler (Chiesi NEXThaler [3200 μg]), followed by a concomitant intravenous infusion of a microtracer ([C]-tanimilast: 18.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!